Elisabetta Marangoni

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Topics

Endoplasmic Reticulum

Estrogen Receptor

Top Venues

Nature communications

Science translational medicine

Molecular oncology

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Marina Bacci, Nicla Lorito, Alfredo Smiriglia, Angela Subbiani, Francesca Bonechi, Giuseppina Comito, Ludivine Morisset, Rania El-Botty, Matteo Benelli, Joanna I López-Velazco, María M Caffarel, Ander Urruticoechea, George Sflomos, Luca Malorni, Michela Corsini, Luigi Ippolito, Elisa Giannoni, Icro Meattini, Vittoria Matafora, Kristina M Havas, Angela Bachi, Paola Chiarugi, Elisabetta Marangoni, Andrea Morandi
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER + breast cancer. Science translational medicine 16 (736) (2024)
Marina Bacci, Nicla Lorito, Alfredo Smiriglia, Angela Subbiani, Francesca Bonechi, Giuseppina Comito, Ludivine Morisset, Rania El-Botty, Matteo Benelli, Joanna I López-Velazco, María M Caffarel, Ander Urruticoechea, George Sflomos, Luca Malorni, Michela Corsini, Luigi Ippolito, Elisa Giannoni, Icro Meattini, Vittoria Matafora, Kristina M Havas, Angela Bachi, Paola Chiarugi, Elisabetta Marangoni, Andrea Morandi
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER + breast cancer. Science translational medicine 16 (736) (2024)
Ozge Saatci, Metin Cetin, Meral Uner, Unal Metin Tokat, Ioulia Chatzistamou, Pelin Gulizar Ersan, Elodie Montaudon, Aytekin Akyol, Sercan Aksoy, Aysegul Uner, Elisabetta Marangoni, Mathew Sajish, Özgür Sahin
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer. Nature communications 14 (1) (2023)
Rania El-Botty, Sophie Vacher, Juliette Mainguené, Adrien Briaux, Sabrina Ibadioune, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Léa Huguet, Laura Sourd, Ludivine Morriset, Sophie Château-Joubert, Thierry Dubois, Virginie Maire, Rosette Lidereau, Audrey Rapinat, David Gentien, Florence Coussy, Ivan Bièche, Elisabetta Marangoni
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers. Molecular oncology (2023)
Petra Ter Brugge, Sarah C Moser, Ivan Bièche, Petra Kristel, Sabrina Ibadioune, Alexandre Eeckhoutte, Roebi de Bruijn, Eline van der Burg, Catrin Lutz, Stefano Annunziato, Julian de Ruiter, Julien Masliah Planchon, Sophie Vacher, Laura Courtois, Rania El-Botty, Ahmed Dahmani, Elodie Montaudon, Ludivine Morisset, Laura Sourd, Léa Huguet, Heloise Derrien, Fariba Nemati, Sophie Chateau-Joubert, Thibaut Larcher, Anne-Vincent Salomon, Didier Decaudin, Fabien Reyal, Florence Coussy, Tatiana Popova, Jelle Wesseling, Marc-Henri Stern, Jos Jonkers, Elisabetta Marangoni
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers. Nature communications 14 (1) (2023)
Arany Soosainathan, Marjan Iravani, Rania El-Botty, John Alexander, Laura Sourd, Ludivine Morisset, Pierre Painsec, Rebecca Orha, Joanna Nikitorowicz-Buniak, Sunil Pancholi, Syed Haider, Mitchell Dowsett, Elisabetta Marangoni, Lesley-Ann Martin, Clare M Isacke
Targeting transcriptional regulation with a CDK9 inhibitor suppresses growth of endocrine- and palbociclib-resistant ER+ breast cancers. Cancer research (2023)
Mads Haugland Haugen, Hedda von der Lippe Gythfeldt, Eivind Valen Egeland, Lisa Svartdal Normann, Abhilash D Pandya, Lise-Lotte Vedin, Siri Juell, Ellen Tenstad, Geir Frode Øy, Alexandr Kristian, Elisabetta Marangoni, Therese Sørlie, Knut Steffensen, Gunhild Mari Maelandsmo, Olav Engebraaten
Liver X receptors induce antiproliferative effects in basal-like breast cancer. Molecular oncology (2023)
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh C Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I Fisher, Eric T Gangl, Hilary J Lewis, Dawn Trueman, Neha Wali, Stuart Charles Williamson, Jennifer I Moss, Elodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas Moss, Gareth A Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E Critchlow, James S Scott, Justin P O Lindemann, Simon T Barry, Teresa Klinowska, Christopher J Morrow, Larissa S Carnevalli
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer research (2023)
Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoîte Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα + breast cancer. EMBO molecular medicine (2023)
Rania El-Botty, Sophie Vacher, Juliette Mainguené, Adrien Briaux, Sabrina Ibadioune, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Léa Huguet, Laura Sourd, Ludivine Morriset, Sophie Château-Joubert, Thierry Dubois, Virginie Maire, Rosette Lidereau, Audrey Rapinat, David Gentien, Florence Coussy, Ivan Bièche, Elisabetta Marangoni
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers. Molecular oncology (2023)
Rania El-Botty, Ludivine Morriset, Elodie Montaudon, Zakia Tariq, Anne Schnitzler, Marina Bacci, Nicla Lorito, Laura Sourd, Léa Huguet, Ahmed Dahmani, Pierre Painsec, Heloise Derrien, Sophie Vacher, Julien Masliah-Planchon, Virginie Raynal, Sylvain Baulande, Thibaut Larcher, Anne-Vincent Salomon, Guillaume Dutertre, Paul-Henri Cottu, Géraldine Gentric, Fatima Mechta-Grigoriou, Scott Hutton, Keltouma Driouch, Ivan Bièche, Andrea Morandi, Elisabetta Marangoni
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nature communications 14 (1) (2023)
Peng Peng, Xiaoyan Qiang, Guoyu Li, Lin Li, Shumao Ni, Qi Yu, Laura Sourd, Elisabetta Marangoni, Chao Hu, Dong Wang, Di Wu, Frank Wu
Tinengotinib (TT-00420), a Novel Spectrum-Selective Small Molecule Kinase Inhibitor, Is Highly Active Against Triple Negative Breast Cancer. Molecular cancer therapeutics (2022)
Gaia Bianco, Mairene Coto-Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Vijaya G Tirunagaru, Marta De Menna, Viola Paradiso, Caner Ercan, Ahmed Dahmani, Elodie Montaudon, Niko Beerenwinkel, Marianna Kruithof de Julio, Luigi M Terracciano, Claudia Lengerke, Rinath M Jeselsohn, Robert C Doebele, Francois-Clement Bidard, Elisabetta Marangoni, Charlotte C K Ng, Salvatore Piscuoglio
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications biology 5 (1) (2022)
Justine Marsolier, Pacôme Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Léa Baudre, Kevin Grosselin, Mylène Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouzé, Anne-Vincent Salomon, Elisabetta Marangoni, Leïla Perié, Céline Vallot
H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nature genetics 54 (4) (2022)
Gaia Bianco, Mairene Coto-Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Vijaya G Tirunagaru, Marta De Menna, Viola Paradiso, Caner Ercan, Ahmed Dahmani, Elodie Montaudon, Niko Beerenwinkel, Marianna Kruithof de Julio, Luigi M Terracciano, Claudia Lengerke, Rinath M Jeselsohn, Robert C Doebele, Francois-Clement Bidard, Elisabetta Marangoni, Charlotte C K Ng, Salvatore Piscuoglio
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications biology 5 (1) (2022)
Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael W Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra Scherer, Matthew H Bailey, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Yuanxin Xi, Jing Wang, Jayamanna Wickramasinghe, Andrew V Kossenkov, Vito W Rebecca, Hua Sun, R Jay Mashl, Sherri R Davies, Ryan Jeon, Christian Frech, Jelena Randjelovic, Jacqueline Rosains, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C O'Farrell, Elodie Modave, Diether Lambrechts, Petra Ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Hyunsoo Kim, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A Dean, Brandi Davis-Dusenbery, Yvonne A Evrard, James H Doroshow, Alana L Welm, Bryan E Welm, Michael T Lewis, Bingliang Fang, Jack A Roth, Funda Meric-Bernstam, Meenhard Herylyn, Michael A Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Claudio Isella, Jeffrey A Moscow, Livio Trusolino, Annette T Byrne, Jos Jonkers, Carol J Bult, Enzo Medico, Jeffrey H Chuang, null null, null null
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature genetics 53 (1) (2021)
Ivan Bièche, Florence Coussy, Rania El-Botty, Sophie Vacher, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, David Gentien, Fabien Reyal, Francesco Ricci, André Nicolas, Caterina Marchio, Anne Vincent-Salomon, Marick Laé, Elisabetta Marangoni
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. Journal of hematology & oncology 14 (1) (2021)
Florence Coussy, Rania El-Botty, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Sophie Leboucher, Ludivine Morisset, Pierre Painsec, Laura Sourd, Léa Huguet, Fariba Nemati, Jean-Luc Servely, Thibaut Larcher, Sophie Vacher, Adrien Briaux, Cécile Reyes, Philippe La Rosa, Georges Lucotte, Tatiana Popova, Pierre Foidart, Nor Eddine Sounni, Agnès Noel, Didier Decaudin, Laëtitia Furhmann, Anne Salomon, Fabien Reyal, Christopher R Mueller, Petra Ter Brugge, Jos Jonkers, Marie-France Poupon, Marc-Henri Stern, Ivan Bièche, Yves Pommier, Elisabetta Marangoni
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Science translational medicine 12 (531) (2021)
Elodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, Ludivine Morisset, Rania El Botty, Léa Huguet, Ahmed Dahmani, Pierre Painsec, Fariba Nemati, Sophie Vacher, Walid Chemlali, Julien Masliah-Planchon, Sophie Château-Joubert, Camilla Rega, Mariana Ferreira Leal, Nikiana Simigdala, Sunil Pancholi, Ricardo Ribas, André Nicolas, Didier Meseure, Anne Vincent-Salomon, Cécile Reyes, Audrey Rapinat, David Gentien, Thibaut Larcher, Mylène Bohec, Sylvain Baulande, Virginie Bernard, Didier Decaudin, Florence Coussy, Muriel Le Romancer, Guillaume Dutertre, Zakia Tariq, Paul-Henri Cottu, Keltouma Driouch, Ivan Bièche, Lesley-Ann Martin, Elisabetta Marangoni
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nature communications 11 (1) (2020)